April 2, 2014
: Am. J. of Respiratory and Critical Care Medicine
Developing a research agenda for primary prevention of chronic lung diseases—an NHLBI perspective
authored by James Kiley, Ph.D., director of NHLBI Division of Lung Diseases, and Gary Gibbons, M.D., director of NHLBI
The NHLBI has a long history of supporting highly productive and pivotal research that has translated into new therapies and improved management for chronic lung diseases. To date, our greatest successes have derived from research focused on the treatment of existing diseases in symptomatic patients, and there has been less research attention on primary prevention of lung diseases. We are intrigued by the promise of new insights into chronic lung disease coming from continuing advances in genetics, the blossoming field of reparative biology, and the applications of new imaging and “omic” technologies in well-characterized patients and populations. These scientific advances embolden us to envision a future in which we challenge the prevailing concept of “chronic lung disease” and contemplate the development of preventive strategies that will preempt the progression to lung disease and/or promote its “remission” toward normal lung physiology and respiratory health.
March 31, 2014
HIV-Infected Men at Increased Risk for Heart Disease, Large Study Finds
The buildup of soft plaque in arteries that nourish the heart is more common and extensive in HIV-infected men than HIV-uninfected men, independent of established cardiovascular disease risk factors, according to a new study by National Institutes of Health grantees. The findings suggest that HIV-infected men are at greater risk for a heart attack than their HIV-uninfected peers, the researchers write in Annals of Internal Medicine.
December 6, 2013
: ASN Kidney News
NHLBI work spans heart, kidney care
This question and answer piece (starting on page 14) features NHLBI director Gary H. Gibbons discussing the intersection between research in cardiovascular disease and kidney disease.
November 19, 2013
Genetic data does not improve anticoagulation control with warfarin
Combining genetic data with clinical information to determine the initial dosage of the blood thinner warfarin, used to prevent blood clots in the circulatory system, was no more effective in achieving stable anticoagulation than using only clinical information, according to a National Institutes of Health-funded clinical trial. In addition, the study found that in African-Americans, anticoagulation control was lower in the genetics-based approach compared to the clinically-based method.
July 12, 2013
: KQED Forum
Genetic mutation holds promise for cholesterol-busting drug
NHLBI Director Dr. Gary Gibbons is interviewed about a genetic mutation that appears linked to low cholesterol levels. Drug companies are now trying to capitaliza on this genetic finding to produce a new cholesterol drug.
July 1, 2013
: NIH Research Matters
Vietnam vets with PTSD more likely to have heart disease
Among male twin Vietnam veterans, those with post-traumatic stress disorder (PTSD) were more than twice as likely to have heart disease 13 years after being diagnosed as twin vets without PTSD. The finding suggests that PTSD may be a risk factor for heart disease.
June 25, 2013
: Emory University
Study links post-traumatic stress disorder and cardiovascular disease
Post-traumatic stress disorder (PTSD) is associated with increased risk of coronary heart disease, according to a recent study led by researchers at Emory’s Rollins School of Public Health and sponsored by the National Institutes of Health.
May 8, 2013
NIH statement on Asthma Month 2013
For Asthma Awareness Month 2013, the National Institutes of Health stands with the international community to renew our dedication to improving the quality of life for the estimated 300 million people living with asthma worldwide. To most effectively manage asthma, we need to address the disproportionate impact of the disease on minorities and families at or below the poverty line. NIH is committed to reducing asthma disparities and improving asthma control for all who live with the disease.
March 26, 2013
EDTA chelation therapy modestly reduces cardiovascular events
Chelation therapy, an unproven alternative medicine in the treatment for heart disease, modestly reduced cardiovascular events for adults aged 50 and older who had suffered a prior heart attack, according to new NIH-supported research.
March 10, 2013
NIH statement on the vitamin component of the Trial to Assess Chelation Therapy
Preliminary results from the vitamin component of the Trial to Assess Chelation Therapy (TACT) were released today during the American College of Cardiology’s 2013 Scientific Sessions. The study found that overall heart attack patients given a combination of high-dose oral vitamins and minerals did not exhibit a significant reduction in recurrent cardiac events over those who did not receive the high-dose vitamins and minerals.
November 15, 2012
: Medill Reports
NIH reports bypass surgery superior to less invasive stent procedure
Stephanie Novak and Brooke Workneh
“The results are really, very striking,” said Dr. Yves Rosenberg, project officer for the study and chief of the Atherothrombosis and Coronary Artery Disease Branch at NHLBI. “They showed a clear advantage of surgery for the group of patients we studied. The advantage was clear across the board.”
November 9, 2012
: NIH Record
Research festival celebrates 125 years of discovery
The 26th annual NIH Research Festival, held Oct. 9-12, was a moveable feast. The plenary session opened with 3 “big vision” talks. NHLBI Director Dr. Gary Gibbons spoke on a systems approach to health inequities. Dr. Jennifer Lippincott-Schwartz of NICHD addressed advances in technology and imaging, and NIAID’s Dr. Ron Germain took the audience on a journey through the immune system.
November 4, 2012
Cardiac bypass surgery superior to non-surgical procedure for adults with diabetes and heart disease
Adults with diabetes and multi-vessel coronary heart disease who underwent cardiac bypass surgery had better overall heart-related outcomes than those who underwent an artery-opening procedure to improve blood flow to the heart muscle, according to the results from an international study.
November 4, 2012
Statement from NHLBI Director Gary H. Gibbons, M.D.
The National Heart, Lung, and Blood Institute (NHLBI) congratulates the principal investigators and scientific team carrying out the Trial to Assess Chelation Therapy (TACT).
November 4, 2012
: The Wall Street Journal
For diabetics, bypasses gain (subscription only)
Diabetic patients with seriously diseased heart arteries are significantly more likely to survive or avoid future attacks by having them treated with bypass surgery than with artery-opening devices called stents, according to a major new study funded by the National Heart, Lung, and Blood Institute.
November 4, 2012
: The New England Journal of Medicine
Strategies for multivessel revascularization in patients with diabetes
Coauthored by Yves Rosenberg, M.D., M.P.H., and Robin Boineau, M.D., Division of Cardiovascular Sciences
Results from the NHLBI-funded Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM) trial showed that bypass surgery was superior to PCI, a non-surgical procedure, in treating patients with diabetes and advanced coronary artery disease.
November 4, 2012
: MedPage Today
FREEDOM: Bypass bests stents for diabetics
Bypass surgery is a better treatment choice than stenting for diabetics with multivessel coronary artery disease, according to recent results from the NHLBI-funded FREEDOM trial.
November 4, 2012
: The Mount Sinai Hospital
Individuals who have diabetes and advanced coronary artery disease have significantly better outcomes with bypass surgery than angioplasty
An international team of researchers led by Valentin Fuster, M.D., Ph.D., Director of Mount Sinai Heart, has found in the first long-term study of its kind that individuals who have diabetes and advanced coronary artery disease (CAD) live longer and are less likely to suffer a non-fatal heart attack when treated with bypass surgery instead of angioplasty.
October 10, 2012
NIH grantees win 2012 Nobel Prize in Chemistry
The 2012 Nobel Prize in chemistry has been awarded to National Institutes of Health grantees Robert J. Lefkowitz, M.D., of the Howard Hughes Medical Institute and Duke University Medical Center, Durham, N.C.; and Brian K. Kobilka, M.D., of the Stanford University School of Medicine, Stanford, Calif., for studies of protein receptors that let body cells sense and respond to outside signals.
September 27, 2012
: NIH Record
NIH scientists receive 2012 Service to America Medals
Dr. Neal Young, chief of NHLBI's Hematology Branch, received the Sammie in the Science and Environment category.
September 7, 2012
Massive trials to test inflammation hypothesis
"This is testing a whole new paradigm, a whole new approach, towards treating atherosclerosis," because anti-inflammatory drugs are not now a therapy of choice, says Michael Lauer, director of the Division of Cardiovascular Sciences at NHLBI.
September 4, 2012
Can treating inflammation reduce risk of cardiovascular disease?
Robin Wulffson M.D.
The new NHLBI-funded Cardiovascular Inflammation Reduction Trial (CIRT) and the Novartis-funded CANTOS study will both test the theory that inflammation plays a significant role in the underlying biology that makes heart disease the number one cause of death and stroke the number four cause of death in the United States.